{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:11:59Z","timestamp":1792141919627,"version":"4.4.0"},"reference-count":156,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunology Research"],"published-print":{"date-parts":[[2021,6,20]]},"abstract":"<jats:p>Increasing evidence indicates a pivotal role of macrophages in innate immunity, which contributes to the pathogenesis of adult-onset Still\u2019s disease (AOSD). Despite the available reviews that summarized the pathogenic role of proinflammatory cytokines in AOSD, a systematic approach focusing on the crucial role of macrophages in this disease is still lacking. This review summarizes the updated functions of macrophages in AOSD and their implication in clinical manifestations and therapeutics. We searched the MEDLINE database using the PubMed interface and reviewed the English-language literature as of 31 March 2021, from 1971 to 2021. We focus on the existing evidence on the pathogenic role of macrophages in AOSD and its implication in clinical characteristics and novel therapeutics. AOSD is an autoinflammatory disease mainly driven by the innate immune response. Among the innate immune responses, macrophage activation is a hallmark of AOSD pathogenesis. The pattern recognition receptors (PRRs) on macrophages recognize pathogen-associated molecular patterns and damage-associated molecular patterns and subsequently cause overproduction of proinflammatory cytokines and recruit adaptive immunity. Some biomarkers, such as ferritin and gasdermin D, reflecting macrophage activation were elevated and correlated with AOSD activity. Given that macrophage activation with the overproduction of proinflammatory cytokines plays a pathogenic role in AOSD, these inflammatory mediators would be the therapeutic targets. Accordingly, the inhibitors to interleukin- (IL-) 1, IL-6, and IL-18 have been shown to be effective in AOSD treatment. Gaining insights into the pathogenic role of macrophages in AOSD can aid in identifying disease biomarkers and therapeutic agents for this disease.<\/jats:p>","DOI":"10.1155\/2021\/8998358","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T22:36:23Z","timestamp":1624314983000},"page":"1-11","source":"Crossref","is-referenced-by-count":18,"title":["An Update on the Pathogenic Role of Macrophages in Adult-Onset Still\u2019s Disease and Its Implication in Clinical Manifestations and Novel Therapeutics"],"prefix":"10.1155","volume":"2021","author":[{"given":"Po-Ku","family":"Chen","sequence":"first","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Translational Medicine Laboratory, Rheumatology and Immunology Center, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-2235","authenticated-orcid":true,"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Translational Medicine Laboratory, Rheumatology and Immunology Center, Taichung, Taiwan"},{"name":"Ph.D. Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","first-page":"1","article-title":"Adult-onset Still\u2019s disease-pathogenesis, clinical manifestations, and new treatment options","volume":"22","author":"S. Kadavath","year":"2015","journal-title":"Annals of Medicine"},{"key":"2","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1097\/CM9.0000000000000538","article-title":"Pathogenesis, disease course, and prognosis of adult-onset Still\u2019s disease: an update and review","volume":"132","author":"M. Y. Wang","year":"2019","journal-title":"Chinese medical journal"},{"key":"3","first-page":"52","article-title":"Clinical features and current treatments of adult-onset Still\u2019s disease: a multicenter survey of 517 patients in China","volume":"37","author":"Q. Y. Hu","year":"2019","journal-title":"Clinical and Experimental Rheumatology"},{"key":"4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","article-title":"Macrophage activation syndrome complicating adult onset Still\u2019s disease: a single center case series and comparison with literature","volume":"45","author":"A. Lenert","year":"2016","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/003693308302800308","article-title":"Adult Still\u2019s disease. A new consideration in pyrexia of unknown origin","volume":"28","author":"J. G. Larkin","year":"1983","journal-title":"Scottish Medical Journal"},{"key":"6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.54.7.587","article-title":"Epidemiology of adult Still's disease: estimate of the incidence by a retrospective studyin west France","volume":"54","author":"G. Magadur-Joly","year":"1995","journal-title":"Annals of the Rheumatic Diseases"},{"key":"7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2188\/jea.7.221","article-title":"Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan","volume":"7","author":"K. Wakai","year":"1997","journal-title":"Journal of Epidemiology"},{"key":"8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03009740510026616","article-title":"Epidemiology and outcome of adult-onset Still's disease in northern Norway","volume":"35","author":"K. J. Evensen","year":"2006","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","article-title":"Autoinflammatory disease reloaded: a clinical perspective","volume":"140","author":"D. L. Kastner","year":"2010","journal-title":"Cell"},{"key":"10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2017.1397656","article-title":"TLRs\/NLRs: shaping the landscape of host immunity","volume":"37","author":"K. Dolasia","year":"2018","journal-title":"International Reviews of Immunology"},{"key":"11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14737159.2019.1615449","article-title":"The role of damage-associated molecular pattern for pathogenesis and biomarkers in adult-onset Still\u2019s disease","volume":"19","author":"J.-Y. Jung","year":"2019","journal-title":"Expert Review of Molecular Diagnostics"},{"key":"12","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult onset Still\u2019s disease","volume":"30","author":"J. H. Choi","year":"2003","journal-title":"The Journal of Rheumatology"},{"key":"13","first-page":"2189","article-title":"Proinflammatory cytokine profiles in the sera and in the pathological tissues of patients with active untreated adult onset Still\u2019s disease","volume":"31","author":"D. Y. Chen","year":"2004","journal-title":"The Journal of Rheumatology"},{"key":"14","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still\u2019s disease","volume":"44","author":"Y. Kawaguchi","year":"2001","journal-title":"Arthritis & Rhematology"},{"key":"15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/ard.2003.013680","article-title":"A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult-onset Still\u2019s disease","volume":"63","author":"D. Y. Chen","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"key":"16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/03009742.2013.824023","article-title":"Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease","volume":"43","author":"K. H. Jung","year":"2014","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"17","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset Still's disease","volume":"55","author":"C. Girard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq284"},{"key":"19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"E. Feist","year":"2018","journal-title":"Nature Reviews Rheumatology"},{"key":"20","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","article-title":"Adult-onset Still\u2019s disease: molecular pathophysiology and therapeutic advances","volume":"78","author":"P. Sfriso","year":"2018","journal-title":"Drugs"},{"key":"21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","article-title":"Adult-onset Still's disease: advances in the treatment","volume":"30","author":"S. Casta\u00f1eda","year":"2016","journal-title":"Best Practice & Research. Clinical Rheumatology"},{"key":"22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/1744666X.2017.1332994","article-title":"Treatment of adult-onset Still's disease: up to date","volume":"13","author":"D. H. Yoo","year":"2017","journal-title":"Expert Review of Clinical Immunology"},{"key":"23","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease","volume":"52","author":"A. A. Fitzgerald","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still\u2019s disease: preliminary experience in France","volume":"67","author":"T. Lequerr\u00e9","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"25","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar3366","article-title":"Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study","volume":"13","author":"K. Laskari","year":"2011","journal-title":"Arthritis Research & Therapy"},{"key":"26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still\u2019s disease","volume":"63","author":"X. Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care and Research"},{"key":"27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14397595.2017.1416924","article-title":"Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still\u2019s disease: a meta-analysis","volume":"28","author":"Y. Ma","year":"2018","journal-title":"Modern Rheumatology"},{"key":"28","first-page":"840","article-title":"Open-label, multicentre, dose-escalating, phase II clinical trial on the safety and efficacy of Tadekining alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"C. Gabay","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"29","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/rheumatology\/kez387","article-title":"The innate immune perspective of autoimmune and autoinflammatory conditions","volume":"58","author":"S. Frizinsky","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B978-0-12-387664-5.00003-0","article-title":"The control of adaptive immune responses by the innate immune system","volume":"109","author":"D. Schenten","year":"2011","journal-title":"Advances in Immunology"},{"key":"31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcp.2016.07.011","article-title":"A novel real time imaging platform to quantify macrophage phagocytosis","volume":"116","author":"T. S. Kapellos","year":"2016","journal-title":"Biochemical Pharmacology"},{"key":"32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/ijms19010092","article-title":"The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis","volume":"19","author":"D. Hirayama","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"key":"33","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"D. M. Mosser","year":"2008","journal-title":"Nature Reviews. Immunology"},{"key":"34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","article-title":"Innate immune pattern recognition: a cell biological perspective","volume":"33","author":"S. W. Brubaker","year":"2015","journal-title":"Annual Review of Immunology"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MCHD-0040-2016"},{"key":"36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.abb.2019.02.008","article-title":"NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways","volume":"670","author":"J. M. Platnich","year":"2019","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"37","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"N. Kelley","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ni.2231","article-title":"Sensing and reacting to microbes through the inflammasomes","volume":"13","author":"L. Franchi","year":"2012","journal-title":"Nature Immunology"},{"key":"39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"F. Martinon","year":"2006","journal-title":"Nature"},{"key":"40","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fimmu.2020.01270","article-title":"Glucose induces IL-1alpha-dependent inflammation and extracellular matrix proteins expression and deposition in renal tubular epithelial cells in diabetic kidney disease","volume":"11","author":"T. Salti","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"41","article-title":"The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine","volume":"6, article e1629","author":"L. Baron","year":"2015","journal-title":"Cell death & disease"},{"key":"42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1172\/JCI63679","article-title":"Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1\u03b2 secretion","volume":"123","author":"S. R. Mulay","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"key":"43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/ard.47.9.764","article-title":"Adult Still\u2019s disease and viral infection","volume":"47","author":"J. M. G. W. Wouters","year":"1988","journal-title":"Annals of the Rheumatic Diseases"},{"key":"44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s10156-007-0503-1","article-title":"Adult Still\u2019s disease associated with cytomegalovirus infection","volume":"13","author":"K. Izumikawa","year":"2007","journal-title":"Journal of Infection and Chemotherapy"},{"key":"45","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/0140-6736(93)91184-N","article-title":"Adult Still\u2019s disease associated with acute human parvovirus B19 infection","volume":"341","author":"J. Pouchot","year":"1993","journal-title":"Lancet"},{"key":"46","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cca.2012.01.027","article-title":"Significant association of past parvovirus B19 infection with cytopenia and arthritis in patients with adult-onset Still\u2019s disease","volume":"413","author":"D. Y. Chen","year":"2012","journal-title":"Clinica Chimica Acta"},{"key":"47","first-page":"1275","article-title":"Adult-onset Still\u2019s disease: an unusual presentation of rubella infection","volume":"122","author":"H. S. K. Huang","year":"1980","journal-title":"Canadian Medical Association Journal"},{"key":"48","first-page":"183","article-title":"Acute hepatitis in a patient with adult-onset Still\u2019s disease","volume":"148","author":"M. Gallo","year":"1997","journal-title":"La Clinica Terapeutica"},{"key":"49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/030097498442307","article-title":"Adult onset Still's disease associated with Epstein-Barr virus infection in a 66-year-old woman","volume":"27","author":"T. Schifter","year":"1998","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3109\/s10165-011-0418-7","article-title":"Onset of adult-onset-Still\u2019s disease following influenza vaccination","volume":"21","author":"K. Yoshioka","year":"2011","journal-title":"Modern Rheumatology"},{"key":"51","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/ard.48.9.781","article-title":"Still\u2019s disease associated with adenovirus infection and defect in adenovirus directed natural killing","volume":"48","author":"A. S. Luder","year":"1989","journal-title":"Annals of the Rheumatic Diseases"},{"key":"52","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2071815","article-title":"Adult onset Still\u2019s disease associated with mycoplasma pneumonae infection and hemophagocytic lymphohistiocytosis","volume":"2016","author":"A. Agnihotri","year":"2016","journal-title":"Case Reports in Medicine"},{"key":"53","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1093\/rheumatology\/keaa213","article-title":"Adult-onset Still\u2019s disease associated with human immunodeficiency virus infection","volume":"59","author":"M. Pichon","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"54","first-page":"12627","article-title":"COVID-19 in Still\u2019s disease","volume":"24","author":"J. F. De Carvalho","year":"2020","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"55","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2665-9913(21)00072-2","article-title":"First manifestation of adult-onset Still\u2019s disease after COVID-19","volume":"3","author":"A. D. Bamidis","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"56","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.8275"},{"key":"57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00898"},{"key":"58","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still\u2019s disease","volume":"13","author":"M. Gerfaud-Valentin","year":"2014","journal-title":"Autoimmunity Reviews"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1161\/hc0702.104183"},{"key":"60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2007.02001.x"},{"key":"61","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0569-3"},{"key":"62","doi-asserted-by":"publisher","DOI":"10.1038\/nature11290"},{"key":"63","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-012-2118-2"},{"key":"64","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s10067-016-3314-x","article-title":"Elevated high-mobility group B1 levels in active adult-onset Still\u2019s disease associated with systemic score and skin raash","volume":"35","author":"J. Y. Jung","year":"2016","journal-title":"Clinical Rheumatology"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8563-7"},{"key":"66","doi-asserted-by":"publisher","DOI":"10.1126\/science.153.3731.80"},{"key":"67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.012511599"},{"key":"68","doi-asserted-by":"publisher","DOI":"10.1186\/ar3828"},{"key":"69","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nri1200","article-title":"Macrophage migration inhibitory factor: a regulator of innate immunity","volume":"3","author":"T. Calandra","year":"2003","journal-title":"Nature Reviews. Immunology"},{"key":"70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2008.01.008"},{"key":"71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/03009740802179701","article-title":"Potential role of macrophage migration inhibitory factor in adult-onset Still's disease","volume":"38","author":"H. Becker","year":"2009","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1297-319X(02)00409-8","article-title":"Ferritin levels in adult Still's disease: any sugar?","volume":"69","author":"B. Fautrel","year":"2002","journal-title":"Joint, Bone, Spine"},{"key":"73","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.5.477"},{"key":"74","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1800-z"},{"key":"75","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0305-6"},{"key":"76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01648"},{"key":"77","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine storm in COVID-19: the current evidence and treatment strategies","volume":"11","author":"Y. Tang","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603389"},{"key":"79","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0968051907078604","article-title":"Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors","volume":"13","author":"M. F. Tsan","year":"2007","journal-title":"Journal of Endotoxin Research"},{"key":"80","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrrheum.2016.61","article-title":"Toll-like receptors and chronic inflammation in rheumatic diseases: new developments","volume":"12","author":"L. A. B. Joosten","year":"2016","journal-title":"Nature Reviews Rheumatology"},{"key":"81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/intimm\/dxx010","article-title":"Role of scavenger receptors as damage-associated molecular pattern receptors in Toll-like receptor activation","volume":"29","author":"K. Komai","year":"2017","journal-title":"International Immunology"},{"key":"82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3892\/ijmm.2014.1755","article-title":"Lipopolysaccharide\/adenosine triphophate induces IL-1\u03b2 and IL-18 secretion through the NLRP3 inflammasome in RAW264.7 murine macrophage cells","volume":"34","author":"Q. Xie","year":"2014","journal-title":"International Journal of Molecular Medicine"},{"key":"83","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s00018-003-3180-y","article-title":"The art of war: innate and adaptive immune responses","volume":"60","author":"P. W. Dempsey","year":"2003","journal-title":"Cellular and Molecular Life Sciences"},{"key":"84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04086-w"},{"key":"85","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161354"},{"key":"86","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9473497"},{"key":"87","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12738"},{"key":"88","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12826"},{"key":"89","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13069","article-title":"Eppur Si Muove: ferritin is essential in modulating inflammation","volume":"191","author":"K. Sharif","year":"2018","journal-title":"Clinical and Experimental Immunology"},{"key":"90","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217618"},{"key":"91","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.11.005"},{"key":"92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"P. Broz","year":"2016","journal-title":"Nature Reviews. Immunology"},{"key":"93","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa814"},{"key":"94","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1422231"},{"key":"95","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: biologic properties and role in disease pathjogenesis","volume":"281","author":"G. Kaplanski","year":"2018","journal-title":"Immunological Reviews"},{"key":"96","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez282"},{"key":"97","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30096-5"},{"key":"98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"C. B. Crayne","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"99","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00296-011-2330-z","article-title":"Cutaneous manifestations associated with adult-onset Still\u2019s disease: important diagnostic values","volume":"32","author":"T. Yamamoto","year":"2012","journal-title":"Rheumatology International"},{"key":"100","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq397"},{"key":"101","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-019-0053-z"},{"key":"102","doi-asserted-by":"publisher","DOI":"10.1038\/srep46652"},{"key":"103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"N. Inoue","year":"2016","journal-title":"Clinical Immunology"},{"key":"104","first-page":"653","article-title":"Interleukin-6: a possible marker of disease activity in adult-onset Still\u2019s disease","volume":"14","author":"M. A. Scheinberg","year":"1996","journal-title":"Clinical and Experimental Rheumatology"},{"key":"105","doi-asserted-by":"publisher","DOI":"10.1002\/art.39332"},{"key":"106","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00124743-200108000-00013","article-title":"Worsening of macrophage activation syndrome in a patient with adult onset Still\u2019s disease after initiation of etanercept therapy","volume":"7","author":"A. Stern","year":"2001","journal-title":"Journal of Clinical Rheumatology"},{"key":"107","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/14397595.2016.1221875","article-title":"Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still\u2019s disease","volume":"7","author":"Y. Tsuchida","year":"2017","journal-title":"Modern Rheumatology"},{"key":"108","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04949-0"},{"key":"109","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170955"},{"key":"110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235326"},{"key":"111","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-185"},{"key":"112","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3899\/jrheum.090662","article-title":"Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases","volume":"37","author":"J. Maruyama","year":"2010","journal-title":"The Journal of Rheumatology"},{"key":"113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820852"},{"key":"114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.02.010"},{"key":"115","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"V. Pascual","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"key":"116","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/879020"},{"key":"117","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.04.002"},{"key":"118","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108068"},{"key":"119","first-page":"47","article-title":"Adult-onset Still\u2019s disease: clinical, serological, and therapeutic considerations","volume":"31","author":"C. Iliou","year":"2013","journal-title":"Clinical and Experimental Rheumatology"},{"key":"120","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111549"},{"key":"121","first-page":"2345","article-title":"Interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease: a meta-analysis of its efficacy and safety","volume":"8","author":"D. Hong","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"key":"122","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez350"},{"issue":"1","key":"123","doi-asserted-by":"crossref","first-page":"187","DOI":"10.55563\/clinexprheumatol\/fsq5vq","article-title":"The treatment of adult-onset Still\u2019s disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature","volume":"39","author":"R. Giacomelli","year":"2021","journal-title":"Clinical and Experimental Rheumatology"},{"key":"124","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006656"},{"key":"125","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"H. E. S\u00f6nmez","year":"2018","journal-title":"Clinical Rheumatology"},{"key":"126","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still's disease-the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"G. Junge","year":"2017","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"127","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 trap rilonacept in refractory adult onset Still\u2019s disease","volume":"71","author":"O. Petryna","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"128","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217155"},{"key":"129","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2021-9"},{"key":"130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nsmb941","article-title":"Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor","volume":"12","author":"G. Skiniotis","year":"2005","journal-title":"Nature Structural & Molecular Biology"},{"key":"131","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"C. A. Hunter","year":"2015","journal-title":"Nature Immunology"},{"key":"132","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1838-6"},{"key":"133","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2008.088179","article-title":"Tocilizumab for multirefractory adult-onset Still\u2019s disease","volume":"68","author":"M. De Bandt","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"134","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10067-010-1553-9","article-title":"A case of refractory adult-onset Still\u2019s disease successfully controlled with tocilizumab and a review of the literature","volume":"29","author":"K. Perdan-Pirkmajer","year":"2010","journal-title":"Clinical Rheumatology"},{"key":"135","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129403"},{"key":"136","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0569-6"},{"key":"137","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/TCRM.S155488","article-title":"Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-baased review","volume":"14","author":"S. Zhou","year":"2018","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"138","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5656320"},{"key":"139","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","article-title":"Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage activation syndrome","volume":"21","author":"M. Kobayashi","year":"2011","journal-title":"Modern Rheumatology"},{"key":"140","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13936"},{"key":"141","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14712598.2019.1590334","article-title":"Tocilizumab for the treatment of adult-onset Still\u2019s disease","volume":"19","author":"S. Casta\u00f1eda","year":"2019","journal-title":"Expert Opinion on Biological Therapy"},{"key":"142","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tips.2008.11.004","article-title":"Interleukin-17 as drug target in human disease","volume":"30","author":"S. Ivanov","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"key":"143","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrrheum.2009.179","article-title":"IL-17 as a future therapeutic target for rheumatoid arthritis","volume":"5","author":"W. B. van den Berg","year":"2009","journal-title":"Nature Reviews Rheumatology"},{"key":"144","doi-asserted-by":"publisher","DOI":"10.1002\/art.27334"},{"key":"145","first-page":"125","article-title":"AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind, proof-of-concept trial","volume":"68","author":"P. Durez","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"146","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.immuni.2015.06.003","article-title":"Proteolytic processing of interleukin-1 family cytokines: variations on a common theme","volume":"42","author":"I. S. Afonina","year":"2015","journal-title":"Immunity"},{"key":"147","article-title":"Prolonged treatment with Tadekinig alfa in adult-onset Still\u2019s disease","volume":"79, article e10","author":"U. Kiltz","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"148","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.12.1398"},{"key":"149","first-page":"iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still\u2019s disease with infliximab: first experiences","volume":"60","author":"H. G. Kraetsch","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"key":"150","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/jcm10061164","article-title":"The pathogenic role of interferons in the hyperinflammatory response on adult-onset Still\u2019s disease and macrophage activation syndrome: paving the way towards new therapeutic targets","volume":"10","author":"I. Di Cola","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"151","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-3127"},{"key":"152","article-title":"Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease","volume":"6, article e001246","author":"M. Kacar","year":"2020","journal-title":"RMD Open"},{"key":"153","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/key414","article-title":"Treatment of refractory adult onset Still\u2019s disease with combination anakinra and baricitinib therapy","volume":"58","author":"C. Ladhari","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"154","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single center in China","volume":"79","author":"Q. Hu","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/03009742.2020.1729405","article-title":"Tofacitinib-induced remission in refractory adult-onset Still\u2019s disease complicated by macrophage activation syndrome","volume":"49","author":"M. Honda","year":"2020","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"156","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08747-8"}],"container-title":["Journal of Immunology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2021\/8998358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2021\/8998358.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2021\/8998358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T02:22:02Z","timestamp":1672539722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jir\/2021\/8998358\/"}},"subtitle":[],"editor":[{"given":"Margarete D.","family":"Bagatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,20]]},"references-count":156,"alternative-id":["8998358","8998358"],"URL":"https:\/\/doi.org\/10.1155\/2021\/8998358","relation":{},"ISSN":["2314-7156","2314-8861"],"issn-type":[{"value":"2314-7156","type":"electronic"},{"value":"2314-8861","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,20]]}}}